MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Liu, Ying ^a   Ding, Yi ^a   Huang, Jing ^a,b   Wang, Shuang ^a   Ni, Wen ^a   Guan, Jian ^a   Li, Qisheng ^a   Zhang, Yuqin ^a   Ding, Yanqing ^a   Chen, Bin ^a   Chen, Longhua ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 141; SHORT HAIRPIN RNA;

ADULT; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SURVIVAL TIME; TIAM1 GENE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84895811856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088393     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. (Pubitemid 40372904)
2. Mazzanti R, Gramantieri L, Bolondi L (2008) Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 29: 130-143. (Pubitemid 351312220)
3. Olsen SK, Brown RS, Siegel AB (2010) Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 3: 55-66.
4. Ng KK, Lo CM, Liu CL, Poon RT, Chan SC, et al. (2008) Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg 143: 68-74, 74.
5. Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, et al. (2007) PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 72 Suppl 1: 52-57. (Pubitemid 350256665)
6. Liu Y, Zhang JB, Qin Y, Wang W, Wei L, et al. (2013) PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1alpha expression and protein stability. Hepatology 58: 692-705.
7. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591.
8. Iorio MV, Croce CM (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27: 5848-5856.
9. Hoffman GR, Cerione RA (2002) Signaling to the Rho GTPases: networking with the DH domain. FEBS Lett 513: 85-91. (Pubitemid 34242983)
10. Minard ME, Kim LS, Price JE, Gallick GE (2004) The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 84: 21-32. (Pubitemid 38388857)
11. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, et al. (1994) Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 85: 645-651. (Pubitemid 24191241)
12. Stebel A, Brachetti C, Kunkel M, Schmidt M, Fritz G (2009) Progression of breast tumors is accompanied by a decrease in expression of the Rho guanine exchange factor Tiam1. Oncol Rep 21: 217-222.
13. Adam L, Vadlamudi RK, McCrea P, Kumar R (2001) Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 276: 28443-28450.
14. Jin H, Li T, Ding Y, Deng Y, Zhang W, et al. (2011) Methylation status of T-lymphoma invasion and metastasis 1 promoter and its overexpression in colorectal cancer. Hum Pathol 42: 541-551.
15. Liu L, Wu DH, Ding YQ (2005) Tiam1 gene expression and its significance in colorectal carcinoma. World J Gastroenterol 11: 705-707. (Pubitemid 40220762)
16. Engers R, Mueller M, Walter A, Collard JG, Willers R, et al. (2006) Prognostic relevance of Tiam1 protein expression in prostate carcinomas. Br J Cancer 95: 1081-1086. (Pubitemid 44606836)
17. Hou M, Tan L, Wang X, Zhu YS (2004) Antisense Tiam1 down-regulates the invasiveness of 95D cells in vitro. Acta Biochim Biophys Sin (Shanghai) 36: 537-540. (Pubitemid 39434134)
18. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, et al. (2002) Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417: 867-871. (Pubitemid 34670335)
19. Zhao L, Liu Y, Sun X, He M, Ding Y (2011) Overexpression of T lymphoma invasion and metastasis 1 predict renal cell carcinoma metastasis and overall patient survival. J Cancer Res Clin Oncol 137: 393-398.
20. Ding Y, Chen B, Wang S, Zhao L, Chen J, et al. (2009) Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. Int J Cancer 124: 653-658.
21. Huang J, Ye X, Guan J, Chen B, Li Q, et al. (2012) Tiam1 is associated with hepatocellular carcinoma metastasis. Int J Cancer 132:90-100.
22. Moriarty CH, Pursell B, Mercurio AM (2010) miR-10b targets Tiam1: implications for Rac activation and carcinoma migration. J Biol Chem 285: 20541-20546.
23. Cottonham CL, Kaneko S, Xu L (2010) miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 285: 35293-35302.
24. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, et al. (2007) Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67: 11612-11620.
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
26. Milazzo M, Fornari F, Gramantieri L (2011) MicroRNA and hepatocellular carcinoma: biology and prognostic significance. Minerva Gastroenterol Dietol 57: 257-271.
27. Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, et al. (2010) Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Biol 42: 1355-1362.
28. Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, et al. (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28: 27-38.
29. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707. (Pubitemid 47437445)
30. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436. (Pubitemid 351185951)
31. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, et al. (2011) Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6: e17745.
32. Zhang L, Deng T, Li X, Liu H, Zhou H, et al. (2010) microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis 31: 559-566.
33. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, et al. (2008) Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 216: 418-427.
34. Du Y, Xu Y, Ding L, Yao H, Yu H, et al. (2009) Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 44: 556-561.
35. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601. (Pubitemid 351627379)
36. Hu W, Wang X, Ding X, Li Y, Zhang X, et al. (2012) MicroRNA-141 represses HBV replication by targeting PPARA. PLoS One 7: e34165.
37. Yu XY, Zhang Z, Liu J, Zhan B, Kong CZ (2013) MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B. Onco Targets Ther 6: 349-354.
38. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005-1017.
39. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.